Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis

BACKGROUND AND AIM: Administration of tenofovir alafenamide (TAF) as prevention or treatment of hepatitis B virus (HBV) reactivation is not well known. The aim of this study is to reveal the efficacy and safety of TAF against HBV reactivation. METHODS: Entecavir (ETV) and TAF were given to 66 and 11...

Descripción completa

Detalles Bibliográficos
Autores principales: Inada, Kento, Kaneko, Shun, Kurosaki, Masayuki, Yamashita, Koji, Kirino, Sakura, Osawa, Leona, Hayakawa, Yuka, Sekiguchi, Shuhei, Higuchi, Mayu, Takaura, Kenta, Maeyashiki, Chiaki, Tamaki, Nobuharu, Yasui, Yutaka, Itakura, Jun, Takahashi, Yuka, Tsuchiya, Kaoru, Nakanishi, Hiroyuki, Okamoto, Ryuichi, Izumi, Namiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454476/
https://www.ncbi.nlm.nih.gov/pubmed/34584979
http://dx.doi.org/10.1002/jgh3.12636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454476/
https://www.ncbi.nlm.nih.gov/pubmed/34584979
http://dx.doi.org/10.1002/jgh3.12636

Ejemplares similares